Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy inpatients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group

CJA Punt; S Suciu; MA Gore; J (Julia) Koller; Wim Kruit; J Thomas; P Patel; D Lienard; Lex Eggermont; U Keilholz

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy inpatients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group

CJA Punt, S Suciu, MA Gore, J (Julia) Koller, Wim Kruit, J Thomas, P Patel, D Lienard, Lex Eggermont, U Keilholz

External organisation

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	2991-2995
Number of pages	5
Journal	European Journal of Cancer
Volume	42
Issue number	1
Publication status	Published - 2006

Research programs

EMC MM-03-47-11
EMC MM-03-86-12

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Punt, CJA., Suciu, S., Gore, MA., Koller, J., Kruit, W., Thomas, J., Patel, P., Lienard, D., Eggermont, L., & Keilholz, U. (2006). Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy inpatients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group. European Journal of Cancer, 42(1), 2991-2995.

Punt, CJA ; Suciu, S ; Gore, MA et al. / Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy inpatients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group. In: European Journal of Cancer. 2006 ; Vol. 42, No. 1. pp. 2991-2995.

@article{ae331da16cea4073a0908afe78c57f54,

title = "Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy inpatients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group",

author = "CJA Punt and S Suciu and MA Gore and Koller, \{J (Julia)\} and Wim Kruit and J Thomas and P Patel and D Lienard and Lex Eggermont and U Keilholz",

year = "2006",

language = "Undefined/Unknown",

volume = "42",

pages = "2991--2995",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

number = "1",

}

Punt, CJA, Suciu, S, Gore, MA, Koller, J, Kruit, W, Thomas, J, Patel, P, Lienard, D, Eggermont, L & Keilholz, U 2006, 'Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy inpatients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group', European Journal of Cancer, vol. 42, no. 1, pp. 2991-2995.

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy inpatients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group. / Punt, CJA; Suciu, S; Gore, MA et al.
In: European Journal of Cancer, Vol. 42, No. 1, 2006, p. 2991-2995.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy inpatients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group

AU - Punt, CJA

AU - Suciu, S

AU - Gore, MA

AU - Koller, J (Julia)

AU - Kruit, Wim

AU - Thomas, J

AU - Patel, P

AU - Lienard, D

AU - Eggermont, Lex

AU - Keilholz, U

PY - 2006

Y1 - 2006

M3 - Article

SN - 0959-8049

VL - 42

SP - 2991

EP - 2995

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 1

ER -

Punt CJA, Suciu S, Gore MA, Koller J, Kruit W, Thomas J et al. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy inpatients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group. European Journal of Cancer. 2006;42(1):2991-2995.